PSU Profiles
Loading...
Keywords
Last Name
Institution

David Claxton

TitleProfessor
InstitutionCollege of Medicine
DepartmentMedicine
Address500 University Drive Hershey PA 17033
Phone7175318399
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    PREFERRED TITLE/ROLE:

    Physician, Professor of Medicine

    EDUCATION:

    M.D., McGill University, 1978
    Internship, Royal Jubilee Hospital, Victoria, BC 1979
    Residency, Royal Victoria Hospital, Montreal, Quebec 1984
    Fellowship, Royal Victoria Hospital 1986
    Fellowship, M.D. Anderson Cancer Center, Texas 1990

    NARRATIVE:

    Dr. Claxton received his MD from McGill University in Montreal Canada in 1978 and completed an Internal Medicine Residency in 1983. He then pursued a Hematology Fellowship followed by an Oncology Fellowship, which he completed at the M.D. Anderson Cancer Center in 1990. He was subsequently a faculty member at M.D. Anderson in the Department of Blood and Marrow Transplantation until he left M.D. Anderson in year 2000 to come to Penn State Hershey Cancer Institute. At Penn State, he was promoted to full Professor. His responsibilities at Penn State have included patient care in the areas of hematological malignancies and leukemia treatments, blood and marrow transplantation, teaching, research, and administration.

    Currently, Dr. Claxton is actively involved in patient care of patients with blood malignancies. His clinical focus is on leukemias and myelodysplastic syndrome and bone marrow transplantation. He teaches medical students, residents, and subspecialty fellows. He has numerous publications in the field of leukemia molecular biology and therapeutics. He has active clinical research interests in leukemia theerapeutics and is also active in translational and bench research and leukemia therapeutics.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Khan N, Oster W, Allen JE, El-Deiry WS. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Cell Cycle. 2017 Nov 20; 1-29. PMID: 29157092.
      View in: PubMed
    2. Doshi UA, Shaw J, Fox TE, Claxton DF, Loughran TP, Kester M. STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia. Signal Transduct Target Ther. 2017; 2:17051. PMID: 29263930.
      View in: PubMed
    3. Schneider C, Bayerl M, Boyer C, Desai R, Claxton D, Van de Louw A. Increased CD13 Expression in Acute Myeloid Leukemia-associated Early Acute Hypoxic Respiratory Failure. Am J Respir Crit Care Med. 2017 Oct 15; 196(8):1077-1080. PMID: 28323433.
      View in: PubMed
    4. Hengst JA, Dick TE, Sharma A, Doi K, Hegde S, Tan SF, Geffert LM, Fox TE, Sharma AK, Desai D, Amin S, Kester M, Loughran TP, Paulson RF, Claxton DF, Wang HG, Yun JK. SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models. Cancer Transl Med. 2017 Jul-Aug; 3(4):109-121. PMID: 28890935.
      View in: PubMed
    5. Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 Aug; 18(8):1061-1075. PMID: 28645776.
      View in: PubMed
    6. Zhu L, Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Palmisiano ND, Wang M, Jia B, Bayerl M, Schell TD, Hohl RJ, Zeng H, Zheng H. Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. J Hematol Oncol. 2017 Jun 19; 10(1):124. PMID: 28629373.
      View in: PubMed
    7. Teye EK, Sido A, Xin P, Finnberg NK, Gokare P, Kawasawa YI, Salzberg AC, Shimko S, Bayerl M, Ehmann WC, Claxton DF, Rybka WB, Drabick JJ, Wang HG, Abraham T, El-Deiry WS, Brodsky RA, J Hohl R, Pu JJ. PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features. Oncotarget. 2017 May 02; 8(18):29887-29905. PMID: 28187452.
      View in: PubMed
    8. Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017 05 01; 28(5):1050-1056. PMID: 28453705.
      View in: PubMed
    9. Salzberg AC, Harris-Becker A, Popova EY, Keasey N, Loughran TP, Claxton DF, Grigoryev SA. Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability. PLoS One. 2017; 12(3):e0173723. PMID: 28301528.
      View in: PubMed
    10. Levy MA, Claxton DF. Therapeutic inhibition of BCL-2 and related family members. Expert Opin Investig Drugs. 2017 Mar; 26(3):293-301. PMID: 28161988.
      View in: PubMed
    11. Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C. Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients. Ann Oncol. 2017 Jan 25. PMID: 28171884.
      View in: PubMed
    12. Tan SF, Liu X, Fox TE, Barth BM, Sharma A, Turner SD, Awwad A, Dewey A, Doi K, Spitzer B, Shah MV, Morad SA, Desai D, Amin S, Zhu J, Liao J, Yun J, Kester M, Claxton DF, Wang HG, Cabot MC, Schuchman EH, Levine RL, Feith DJ, Loughran TP. Acid ceramidase is upregulated in AML and represents a novel therapeutic target. Oncotarget. 2016 Dec 13; 7(50):83208-83222. PMID: 27825124.
      View in: PubMed
    13. Stefanski M, Jamis-Dow C, Bayerl M, Desai RJ, Claxton DF, Van de Louw A. Chest radiographic and CT findings in hyperleukocytic acute myeloid leukemia: A retrospective cohort study of 73 patients. Medicine (Baltimore). 2016 Nov; 95(44):e5285. PMID: 27858899.
      View in: PubMed
    14. Kirschbaum MH, Frankel P, Synold TW, Zain J, Claxton D, Tuscano J, Newman EM, Gandara DR, Lara PN. A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol. 2018 02; 180(3):445-448. PMID: 27650362.
      View in: PubMed
    15. Liu Q, Chen L, Atkinson JM, Claxton DF, Wang HG. Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model. Cell Death Dis. 2016 Sep 08; 7(9):e2361. PMID: 27607576.
      View in: PubMed
    16. Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016 11 03; 128(18):2199-2205. PMID: 27601462.
      View in: PubMed
    17. Morad SA, Ryan TE, Neufer PD, Zeczycki TN, Davis TS, MacDougall MR, Fox TE, Tan SF, Feith DJ, Loughran TP, Kester M, Claxton DF, Barth BM, Deering TG, Cabot MC. Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia. J Lipid Res. 2016 07; 57(7):1231-42. PMID: 27140664; PMCID: PMC4918852 [Available on 07/01/17].
    18. Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, Rybka WB, George MR, Zeng H, Zheng H. T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients. Clin Cancer Res. 2016 Jun 15; 22(12):3057-66. PMID: 26763253.
      View in: PubMed
    19. Van de Louw A, Schneider CW, Desai RJ, Claxton DF. Initial respiratory status in hyperleukocytic acute myeloid leukemia: prognostic significance and effect of leukapheresis. Leuk Lymphoma. 2016; 57(6):1319-26. PMID: 26374497.
      View in: PubMed
    20. Van de Louw A, Desai RJ, Schneider CW, Claxton DF. Hypoxemia During Extreme Hyperleukocytosis: How Spurious? Respir Care. 2016 Jan; 61(1):8-14. PMID: 26420901.
      View in: PubMed
    21. Robuccio A, Ssentongo P, Sather MD, Claxton DF, Gilliam FG. Intractable myoclonic seizures in an allogeneic stem cell transplant recipient: A rare case of myoclonic epilepsy. Epilepsy Behav Case Rep. 2015; 4:48-51. PMID: 26288756; PMCID: PMC4536288.
    22. Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, Zeng H, Schell TD, Zheng H. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J. 2015 Jul 31; 5:e330. PMID: 26230954; PMCID: PMC4526784.
    23. Morad SA, Tan SF, Feith DJ, Kester M, Claxton DF, Loughran TP, Barth BM, Fox TE, Cabot MC. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics. Biochim Biophys Acta. 2015 Jul; 1851(7):919-28. PMID: 25769964; PMCID: PMC4459585.
    24. Schimmer AD, Raza A, Carter TH, Claxton D, Erba H, DeAngelo DJ, Tallman MS, Goard C, Borthakur G. A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. PLoS One. 2014; 9(10):e108694. PMID: 25285531; PMCID: PMC4186779.
    25. McGill CM, Alba-Rodriguez EJ, Li S, Benson CJ, Ondrasik RM, Fisher LN, Claxton DF, Barth BM. Extracts of Devil's club (Oplopanax horridus) exert therapeutic efficacy in experimental models of acute myeloid leukemia. Phytother Res. 2014 Sep; 28(9):1308-14. PMID: 25340187.
      View in: PubMed
    26. Barth BM, Keasey NR, Wang X, Shanmugavelandy SS, Rampal R, Hricik T, Cabot MC, Kester M, Wang HG, Shultz LD, Tallman MS, Levine RL, Loughran TP, Claxton DF. Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2r?null Mice for Preclinical Ceramide-Based Therapeutic Evaluation. J Leuk (Los Angel). 2014 Sep; 2(3). PMID: 28239612.
      View in: PubMed
    27. Abbi KK, Rybka W, Ehmann WC, Claxton DF. Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jan; 15(1):41-6. PMID: 25085441.
      View in: PubMed
    28. Doi K, Liu Q, Gowda K, Barth BM, Claxton D, Amin S, Loughran TP, Wang HG. Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression. Cancer Biol Ther. 2014 Aug; 15(8):1077-86. PMID: 24842334; PMCID: PMC4119075.
    29. Doi K, Gowda K, Liu Q, Lin JM, Sung SS, Dower C, Claxton D, Loughran TP, Amin S, Wang HG. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells. Cancer Biol Ther. 2014; 15(12):1688-99. PMID: 25535900; PMCID: PMC4623387.
    30. Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O'Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013 Oct 29; 6(1):81. PMID: 24283202; PMCID: PMC4176265.
    31. Tiley S, Claxton D. Clofarabine in the treatment of acute myeloid leukemia in older adults. Ther Adv Hematol. 2013 Feb; 4(1):5-13. PMID: 23610610; PMCID: PMC3629760.
    32. Vasekar M, Allen JE, Joudeh J, Claxton D. Emerging molecular therapies for the treatment of acute lymphoblastic leukemia. Adv Exp Med Biol. 2013; 779:341-58. PMID: 23288648.
      View in: PubMed
    33. Bisen A, Claxton DF. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms. Adv Exp Med Biol. 2013; 779:179-96. PMID: 23288640.
      View in: PubMed
    34. Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov; 13(11):1096-104. PMID: 23075701; PMCID: PMC4004358.
    35. Abbi KK, Zhu J, Ehmann WC, Epner E, Carraher M, Mierski J, Talamo G, Lucas K, Rybka W, Claxton D. G-CSF mobilized vs conventional donor lymphocytes for therapy of relapse or incomplete engraftment after allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2013 Mar; 48(3):357-62. PMID: 22863726.
      View in: PubMed
    36. Tacelosky DM, Creecy AE, Shanmugavelandy SS, Smith JP, Claxton DF, Adair JH, Kester M, Barth BM. Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer. Discov Med. 2012 Apr; 13(71):275-85. PMID: 22541615.
      View in: PubMed
    37. Joudeh J, Claxton D. Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms. Expert Opin Investig Drugs. 2012 Mar; 21(3):363-73. PMID: 22324354.
      View in: PubMed
    38. Karch J, Zhu J, Ehmann WC, Claxton D. Clofarabine and CY do not yield reliable engraftment of hematopoietic stem cells. Bone Marrow Transplant. 2012 Aug; 47(8):1134-5. PMID: 22080968.
      View in: PubMed
    39. Claxton D, Erba HP, Faderl S, Arellano M, Lyons RM, Kovacsovics T, Gabrilove J, Huebner D, Gandhi PJ, Kantarjian H. Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. Leuk Lymphoma. 2012 Mar; 53(3):435-40. PMID: 21877883.
      View in: PubMed
    40. Barth BM, I Altinoglu E, Shanmugavelandy SS, Kaiser JM, Crespo-Gonzalez D, DiVittore NA, McGovern C, Goff TM, Keasey NR, Adair JH, Loughran TP, Claxton DF, Kester M. Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano. 2011 Jul 26; 5(7):5325-37. PMID: 21675727.
      View in: PubMed
    41. Claxton DF. Out foxing bcr-abl. Cancer Biol Ther. 2011 Apr 15; 11(8):769-70. PMID: 21358259.
      View in: PubMed
    42. Keasey N, Herse Z, Chang S, Liggitt DH, Lay M, Fairman J, Claxton DF. A non-coding cationic lipid DNA complex produces lasting anti-leukemic effects. Cancer Biol Ther. 2010 Sep 15; 10(6):625-31. PMID: 20647744; PMCID: PMC3040951.
    43. Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010 Feb 01; 28(4):549-55. PMID: 20026805.
      View in: PubMed
    44. Talamo GP, Ibrahim S, Claxton D, Tricot GJ, Fink LM, Zangari M. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood Coagul Fibrinolysis. 2009 Jul; 20(5):337-9. PMID: 19367157.
      View in: PubMed
    45. Ibrahim S, Claxton DF. SIRS criteria in prediction of septic shock in hospitalized patients with hematologic malignancies. Cancer Biol Ther. 2009 Jun; 8(12):1101. PMID: 19652525.
      View in: PubMed
    46. Talamo G, Liao J, Bayerl MG, Claxton DF, Zangari M. Oral administration of analgesia and anxiolysis for pain associated with bone marrow biopsy. Support Care Cancer. 2010 Mar; 18(3):301-5. PMID: 19455356.
      View in: PubMed
    47. Talamo G, Claxton DF, Dougherty DW, Ehmann CW, Sivik J, Drabick JJ, Rybka W. BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma. Bone Marrow Transplant. 2009 Aug; 44(3):157-61. PMID: 19204716.
      View in: PubMed
    48. Talamo G, Claxton D, Tricot G, Fink L, Zangari M. Response to bortezomib in refractory type I cryoglobulinemia. Am J Hematol. 2008 Nov; 83(11):883-4. PMID: 18756542.
      View in: PubMed
    49. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009 Jan 08; 113(2):299-305. PMID: 18931344; PMCID: PMC4968372.
    50. von Reyn Cream L, Ehmann WC, Rybka WB, Claxton DF. Sirolimus in unmanipulated haploidentical cell transplantation. Bone Marrow Transplant. 2008 Dec; 42(11):765-6. PMID: 18695659.
      View in: PubMed
    51. Bayerl MG, Bruggeman RD, Conroy EJ, Hengst JA, King TS, Jimenez M, Claxton DF, Yun JK. Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk Lymphoma. 2008 May; 49(5):948-54. PMID: 18452097.
      View in: PubMed
    52. Zhao W, Claxton DF, Medeiros LJ, Lu D, Vadhan-Raj S, Kantarjian HM, Nguyen MH, Bueso-Ramos CE. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22). Am J Surg Pathol. 2006 Nov; 30(11):1436-44. PMID: 17063086.
      View in: PubMed
    53. Popova EY, Claxton DF, Lukasova E, Bird PI, Grigoryev SA. Epigenetic heterochromatin markers distinguish terminally differentiated leukocytes from incompletely differentiated leukemia cells in human blood. Exp Hematol. 2006 Apr; 34(4):453-62. PMID: 16569592.
      View in: PubMed
    54. Claxton DF, Ehmann C, Rybka W. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. Br J Haematol. 2005 Jul; 130(2):256-64. PMID: 16029454.
      View in: PubMed
    55. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23. PMID: 15048145.
      View in: PubMed
    56. Claxton D, Kao SF. Autologous immunotherapy for human leukemias. Blood Cells Mol Dis. 2003 Jul-Aug; 31(1):121-4. PMID: 12850495.
      View in: PubMed
    57. Ye CC, Echeverri C, Anderson JE, Smith JL, Glassman A, Gulley ML, Claxton D, Craig FE. T-cell blast crisis of chronic myelogenous leukemia manifesting as a large mediastinal tumor. Hum Pathol. 2002 Jul; 33(7):770-3. PMID: 12196931.
      View in: PubMed
    58. Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol. 2001 Aug; 67(4):227-33. PMID: 11443634.
      View in: PubMed
    59. Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt S. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001 Jun; 27(12):1221-5. PMID: 11548839.
      View in: PubMed
    60. Shimoni A, Smith TL, Aleman A, Weber D, Dimopoulos M, Anderlini P, Andersson B, Claxton D, Ueno NT, Khouri I, Donato M, Korbling M, Alexanian R, Champlin R, Giralt S. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant. 2001 Apr; 27(8):821-8. PMID: 11477439.
      View in: PubMed
    61. Claxton D, Choudhury A. Potential for therapy with AML-derived dendritic cells. Leukemia. 2001 Apr; 15(4):668-9. PMID: 11368375.
      View in: PubMed
    62. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Feb 01; 97(3):631-7. PMID: 11157478.
      View in: PubMed
    63. Claxton DF, McMannis J, Champlin R, Choudhury A. Therapeutic potential of leukemia-derived dendritic cells: preclinical and clinical progress. Crit Rev Immunol. 2001; 21(1-3):147-55. PMID: 11642601.
      View in: PubMed
    64. Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H, Khouri IF, Folloder J, Ueno NT, Mehra R, Ippoliti C, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Anderlini P, Andersson BS, Champlin R. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant. 2000; 6(2A):190-7. PMID: 10816027.
      View in: PubMed
    65. Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Körbling M, Giralt S, Gajewski J, Fischer H, Donato M, Cleary K, Claxton D, Chan KW, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999 Oct; 24(7):763-8. PMID: 10516680.
      View in: PubMed
    66. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, Körbling M, Huh YO, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999 Aug 15; 94(4):1465-70. PMID: 10438735.
      View in: PubMed
    67. Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Körbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32. PMID: 10416001.
      View in: PubMed
    68. Choudhury BA, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, Sutaria S, Sinha I, Champlin RE, Claxton DF. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 1999 Feb 01; 93(3):780-6. PMID: 9920826.
      View in: PubMed
    69. Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M. Apoptosis. Molecules and mechanisms. Adv Exp Med Biol. 1999; 457:217-36. PMID: 10500797.
      View in: PubMed
    70. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998 Dec; 16(12):3803-9. PMID: 9850025.
      View in: PubMed
    71. Rahman Z, Kavanagh J, Champlin R, Giles R, Hanania E, Fu S, Zu Z, Mehra R, Holmes F, Kudelka A, Claxton D, Verschraegen C, Gajewski J, Andreeff M, Heimfeld S, Berenson R, Ellerson D, Calvert L, Mechetner E, Holzmayer T, Dayne A, Hamer J, Bachier C, Ostrove J, Deisseroth A, et al. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res. 1998 Nov; 4(11):2717-21. PMID: 9829734.
      View in: PubMed
    72. Guo XY, Cuillerot JM, Wang T, Wu Y, Arlinghaus R, Claxton D, Bachier C, Greenberger J, Colombowala I, Deisseroth AB. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells. Oncogene. 1998 Aug 20; 17(7):825-33. PMID: 9779999.
      View in: PubMed
    73. Khouri IF, Keating M, Körbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998 Aug; 16(8):2817-24. PMID: 9704734.
      View in: PubMed
    74. Le XF, Claxton D, Kornblau S, Fan YH, Mu ZM, Chang KS. Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in acute myelogenous leukemia. Eur J Haematol. 1998 Apr; 60(4):217-25. PMID: 9579874.
      View in: PubMed
    75. Liang H, Fairman J, Claxton DF, Nowell PC, Green ED, Nagarajan L. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. Proc Natl Acad Sci U S A. 1998 Mar 31; 95(7):3781-5. PMID: 9520444; PMCID: PMC19914.
    76. Ueno NT, Rondón G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Körbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998 Mar; 16(3):986-93. PMID: 9508181.
      View in: PubMed
    77. Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, Rodriguez J, Giralt S, Romaguera J, Rodriguez A, Preti A, Andersson B, Khouri I, Claxton D, de Lima M, Donato M, Anderlini P, Gajewski J, Cabanillas F, van Besien K. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol. 1998 Jan; 16(1):63-9. PMID: 9440724.
      View in: PubMed
    78. Choudhury A, Toubert A, Sutaria S, Charron D, Champlin RE, Claxton DF. Human leukemia-derived dendritic cells: ex-vivo development of specific antileukemic cytotoxicity. Crit Rev Immunol. 1998; 18(1-2):121-31. PMID: 9419454.
      View in: PubMed
    79. Cao W, Britos-Bray M, Claxton DF, Kelley CA, Speck NA, Liu PP, Friedman AD. CBF beta-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells. Oncogene. 1997 Sep; 15(11):1315-27. PMID: 9315100.
      View in: PubMed
    80. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Kørbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15; 89(12):4531-6. PMID: 9192777.
      View in: PubMed
    81. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreeff M, Champlin RE. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1997 Feb 15; 89(4):1133-42. PMID: 9028934.
      View in: PubMed
    82. Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Deisseroth AB, et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A. 1996 Dec 24; 93(26):15346-51. PMID: 8986814; PMCID: PMC26407.
    83. Körbling M, Chan KW, Anderlini P, Seong D, Durett A, Langlinais A, Przepiorka D, Gajewski J, Miller P, Sundberg J, Alilaen P, Bojko P, Mirza N, Claxton D, van Besien K, Khouri I, Andersson B, Mehra R, Champlin R. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors. Bone Marrow Transplant. 1996 Nov; 18(5):885-90. PMID: 8932841.
      View in: PubMed
    84. Patmasiriwat P, Fraizer GC, Claxton D, Kantarjian H, Saunders GF. Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities. Leukemia. 1996 Jul; 10(7):1127-33. PMID: 8683991.
      View in: PubMed
    85. Zent CS, Mathieu C, Claxton DF, Zhang DE, Tenen DG, Rowley JD, Nucifora G. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties. Proc Natl Acad Sci U S A. 1996 Feb 06; 93(3):1044-8. PMID: 8577711; PMCID: PMC40027.
    86. Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D, Deisseroth AB. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res. 1995 Sep; 1(9):1051-7. PMID: 9816079.
      View in: PubMed
    87. Talpaz M, Kantarjian H, Liang J, Calvert L, Hamer J, Tibbits P, Durett A, Claxton D, Giralt S, Khouri I, et al. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood. 1995 Jun 01; 85(11):3257-63. PMID: 7756658.
      View in: PubMed
    88. Fu S, Consoli U, Hanania EG, Zu Z, Claxton DF, Andreeff M, Deisseroth AB. PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells. Clin Cancer Res. 1995 Jun; 1(6):583-90. PMID: 9816019.
      View in: PubMed
    89. Anderlini P, Przepiorka D, Luna M, Langford L, Andreeff M, Claxton D, Deisseroth AB. Acanthamoeba meningoencephalitis after bone marrow transplantation. Bone Marrow Transplant. 1994 Sep; 14(3):459-61. PMID: 7994273.
      View in: PubMed
    90. Fairman J, Claxton D, Williman CL, Deisseroth AB, Nagarajan L. Development of a sensitive PCR to detect allele loss in a model hematopoietic neoplasm. PCR Methods Appl. 1994 Aug; 4(1):6-12. PMID: 9018310.
      View in: PubMed
    91. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 1994 May 15; 83(10):3068-76. PMID: 7514051.
      View in: PubMed
    92. Claxton DF, Liu P, Hsu HB, Marlton P, Hester J, Collins F, Deisseroth AB, Rowley JD, Siciliano MJ. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood. 1994 Apr 01; 83(7):1750-6. PMID: 8142642.
      View in: PubMed
    93. Nagarajan L, Zavadil J, Claxton D, Lu X, Fairman J, Warrington JA, Wasmuth JJ, Chinault AC, Sever CE, Slovak ML, et al. Consistent loss of the D5S89 locus mapping telomeric to the interleukin gene cluster and centromeric to EGR-1 in patients with 5q- chromosome. Blood. 1994 Jan 01; 83(1):199-208. PMID: 8274735.
      View in: PubMed
    94. Liu P, Tarlé SA, Hajra A, Claxton DF, Marlton P, Freedman M, Siciliano MJ, Collins FS. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science. 1993 Aug 20; 261(5124):1041-4. PMID: 8351518.
      View in: PubMed
    95. Reading CL, Estey EH, Huh YO, Claxton DF, Sanchez G, Terstappen LW, O'Brien MC, Baron S, Deisseroth AB. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood. 1993 Jun 01; 81(11):3083-90. PMID: 8499643.
      View in: PubMed
    96. Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Andersson B, Claxton D. Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine. Hum Gene Ther. 1993 Feb; 4(1):71-85. PMID: 8461383.
      View in: PubMed
    97. Deisseroth AB, Hanania EG, Fu S, Claxton D, Andreeff M, Champlin R, Kavanagh J, Hortobagyi G, Holmes F, Reading C, et al. Genetic therapy of human neoplastic disease. J Hematother. 1993; 2(3):373-5. PMID: 7921999.
      View in: PubMed
    98. Claxton DF, Reading CL, Nagarajan L, Tsujimoto Y, Andersson BS, Estey E, Cork A, Huh YO, Trujillo J, Deisseroth AB. Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood. 1992 Aug 01; 80(3):582-6. PMID: 1353379.
      View in: PubMed
    99. Etkin M, Filaccio M, Ellerson D, Suh SP, Claxton D, Gaozza E, Brenner M, Moen R, Belmont J, Moore KA, et al. Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals. Hum Gene Ther. 1992 Apr; 3(2):137-45. PMID: 1391033.
      View in: PubMed
    100. Claxton D, Deisseroth A, Talpaz M, Reading C, Kantarjian H, Trujillo J, Stass S, Gooch G, Spitzer G. Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia. Blood. 1992 Feb 15; 79(4):997-1002. PMID: 1371081.
      View in: PubMed
    101. Claxton D, Suh SP, Filaccio M, Ellerson D, Gaozza E, Andersson B, Brenner M, Reading C, Feinberg A, Moen R, et al. Molecular analysis of retroviral transduction in chronic myelogenous leukemia. Hum Gene Ther. 1991; 2(4):317-21. PMID: 1665348.
      View in: PubMed
    102. Claxton D, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU, Talpaz M. Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia. Acta Haematol. 1990; 83(3):149-51. PMID: 2109455.
      View in: PubMed
    103. Sullivan AK, Claxton D, Shematek G, Wang H. Cellular composition of rat bone marrow stroma. Antigen-defined subpopulations. Lab Invest. 1989 May; 60(5):667-76. PMID: 2716282.
      View in: PubMed
    Claxton's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _